These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 35863357)
1. [Current Studies and Evidence in Cholangiocarcinoma]. Zimpel C; Mitzlaff K; Jasper NA; Marquardt JU Zentralbl Chir; 2022 Aug; 147(4):389-397. PubMed ID: 35863357 [TBL] [Abstract][Full Text] [Related]
2. Future directions in the treatment of cholangiocarcinoma. Zhu AX Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434 [TBL] [Abstract][Full Text] [Related]
3. Systemic Treatment for Cholangiocarcinoma. Sookprasert A; Wirasorn K; Chindaprasirt J; Watcharenwong P; Sanlung T; Putraveephong S Recent Results Cancer Res; 2023; 219():223-244. PubMed ID: 37660335 [TBL] [Abstract][Full Text] [Related]
4. Role of molecular genetics in the clinical management of cholangiocarcinoma. Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744 [TBL] [Abstract][Full Text] [Related]
6. Proximal biliary tumors. Brown KM; Geller DA Surg Clin North Am; 2014 Apr; 94(2):311-23. PubMed ID: 24679423 [TBL] [Abstract][Full Text] [Related]
7. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma. Lodl E; Ramnaraign B; Sahin I; Wheeler S J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888 [TBL] [Abstract][Full Text] [Related]
8. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558 [TBL] [Abstract][Full Text] [Related]
9. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Bekaii-Saab TS; Bridgewater J; Normanno N Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504 [TBL] [Abstract][Full Text] [Related]
11. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Schweitzer N; Vogel A Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433 [TBL] [Abstract][Full Text] [Related]
12. Infigratinib for cholangiocarcinoma. Sadeghi S Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868 [TBL] [Abstract][Full Text] [Related]
13. Advances in targeted therapy of cholangiocarcinoma. Li Y; Yu J; Zhang Y; Peng C; Song Y; Liu S Ann Med; 2024 Dec; 56(1):2310196. PubMed ID: 38359439 [TBL] [Abstract][Full Text] [Related]
15. Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities. Høgdall D; O'Rourke CJ; Andersen JB Adv Cancer Res; 2022; 156():343-366. PubMed ID: 35961705 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study. Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679 [TBL] [Abstract][Full Text] [Related]
17. Liver transplantation for intra- and extrahepatic cholangiocarcinoma. Schmeding M; Neumann UP Ann Transplant; 2013 Jan; 18():1-8. PubMed ID: 23792495 [TBL] [Abstract][Full Text] [Related]
18. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Spolverato G; Glavas D; Hewitt DB; Brown ZJ; Capelli G; Bergamo F; Rizzato MD; Pawlik TM Expert Opin Pharmacother; 2022 Mar; 23(4):473-481. PubMed ID: 34964678 [TBL] [Abstract][Full Text] [Related]